CN113633761A - 一种生物酶消炎抑菌修护凝胶及其制备方法 - Google Patents
一种生物酶消炎抑菌修护凝胶及其制备方法 Download PDFInfo
- Publication number
- CN113633761A CN113633761A CN202110922711.4A CN202110922711A CN113633761A CN 113633761 A CN113633761 A CN 113633761A CN 202110922711 A CN202110922711 A CN 202110922711A CN 113633761 A CN113633761 A CN 113633761A
- Authority
- CN
- China
- Prior art keywords
- bacteriostatic
- bio
- enzyme
- extract
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 28
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 28
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 24
- 230000003385 bacteriostatic effect Effects 0.000 title claims abstract description 20
- 230000008439 repair process Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title description 6
- 238000001879 gelation Methods 0.000 title description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 15
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 14
- 229960000458 allantoin Drugs 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 229940069521 aloe extract Drugs 0.000 claims abstract description 8
- 239000002562 thickening agent Substances 0.000 claims abstract description 8
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940088598 enzyme Drugs 0.000 claims description 34
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 13
- 241000208680 Hamamelis mollis Species 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 5
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 4
- 102000016943 Muramidase Human genes 0.000 claims description 4
- 108010014251 Muramidase Proteins 0.000 claims description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 4
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 4
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 4
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 4
- 229960000274 lysozyme Drugs 0.000 claims description 4
- 239000004325 lysozyme Substances 0.000 claims description 4
- 235000010335 lysozyme Nutrition 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229940118846 witch hazel Drugs 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims 1
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 claims 1
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 claims 1
- 229940100524 ethylhexylglycerin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 101150017120 sod gene Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 230000004054 inflammatory process Effects 0.000 abstract description 17
- 230000008961 swelling Effects 0.000 abstract description 15
- 241000894006 Bacteria Species 0.000 abstract description 13
- 208000003251 Pruritus Diseases 0.000 abstract description 13
- 210000004400 mucous membrane Anatomy 0.000 abstract description 10
- 230000007803 itching Effects 0.000 abstract description 7
- 244000045947 parasite Species 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 210000001215 vagina Anatomy 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000004888 barrier function Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 230000005906 menstruation Effects 0.000 abstract description 3
- 210000001672 ovary Anatomy 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 210000004291 uterus Anatomy 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 32
- 230000000694 effects Effects 0.000 description 17
- 239000000499 gel Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000003628 erosive effect Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 2
- 241000246044 Sophora flavescens Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000026351 Fallopian Tube disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- -1 anthraquinone compounds Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000011404 female reproductive system disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 208000015317 vulvar disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于生活卫生保健领域。一种生物酶消炎抑菌修护凝胶，包括以下按质量百分比计算的组分：增稠剂0.7‑1.4％、尿囊素0.6‑1％、复合生物酶0.5‑1％、丁二醇1‑3％、苦参提取物0.1‑0.5％、芦荟提取物0.5‑3％以及余量的水。本发明凝胶可有效清除自由基，抗氧化，延缓衰老，滋养嫩白，杀菌消炎，抑菌消肿，清洁排毒，驱虫止痒，修复黏膜，愈合损伤，护理子宫，保养卵巢，调经止痛，保湿滋润，收缩紧致阴道，防止干涩，靶向调理和预防各种妇科疾病，改善私处环境，修复黏膜屏障功能，赋活细胞，激发子宫环境年轻态。
Description
技术领域
本发明属于生活卫生保健领域，具体涉及一种生物酶消炎抑菌修护凝胶及其制备方法。
背景技术
女性生殖系统疾病即为妇科疾病，妇科疾病范围广，包括外阴疾病、阴道疾病、子宫疾病、输卵管疾病、卵巢疾病等。妇科疾病是女性常见病、多发病，主要症状有阴道分泌物增多，外阴瘙痒。极性附件炎还伴有腹痛、发热等症状，慢性附件炎伴有腹痛、白带增多等症状。由于对妇科疾病缺乏认知，身体保健不当，生活习惯不良导致自体免疫力底下等现状，使妇女生理健康每况愈下，导致妇科疾病缠身，久治不愈，反复发作，给正常生活和工作造成了极大不便。
常见的妇科疾病有宫颈糜烂、阴道瘙痒等。宫颈糜烂宫颈柱状上皮异位，细菌感染、手术操作等导致宫颈柱状上皮增生外移覆盖创面取代磷状上皮，严重的可诱发宫颈癌，临床症状有接触性出血，白带增多、发黄和异味。阴道瘙痒是由于炎症造成的阴道粘膜充血和肿胀，炎症分泌的异常分泌物刺激阴道粘膜，加重瘙痒，甚至会出现粘膜破损。
现有的私处修复产品，大部分以抗生素或阴离子作为杀菌剂和抑制炎症，杀菌效率低，难以做到药到病除，见效慢，疗程长，易反复发作，特别是对宫颈糜烂无显著效果。因此，需要一种见效快、效果好、可彻底根除妇科疾病的私处修复凝胶。
发明内容
本发明所要解决的技术问题是提供一种生物酶消炎抑菌修护凝胶，该凝胶可有效清除自由基，抗氧化，延缓衰老，滋养嫩白，杀菌消炎，抑菌消肿，清洁排毒，驱虫止痒，修复黏膜，愈合损伤，护理子宫，保养卵巢，调经止痛，保湿滋润，收缩紧致阴道，防止干涩，靶向调理和预防各种妇科疾病，改善私处环境，修复黏膜屏障功能，赋活细胞，激发子宫环境年轻态。
本发明的技术方案如下：
一种生物酶消炎抑菌修护凝胶，包括以下按质量百分比计算的组分：增稠剂0.7-1.4％、尿囊素0.6-1％、复合生物酶0.5-1％、丁二醇1-3％、苦参提取物0.1-0.5％、芦荟提取物0.5-3％、金缕梅提取物8-15％以及余量的水。
A.尿囊素
尿囊素具有避光、杀菌防腐、止痛、抗氧化作用，能使皮肤保持水分、滋润和柔软，具有促进细胞生长、加快伤口愈合、软化角质蛋白等生理功能，加速细胞增殖分化，迅速形成表皮层，实现肌肤修复、诱导新生、细腻嫩肤的效果。但尿囊素水溶性差，于一般的护肤品中添加量仅为0.3％，超过该剂量就会析出，水剂产品会呈现出针状凝结物，结晶等。申请人经大量实验证明了：低浓度的尿囊素对肌肤的护理和修复来说是远远不够的，因而限制了尿囊素在护肤品和药品中的应用。实验证明在护肤品中尿囊素添加量达0.6％及以上，其优异的护肤新能才能显现。本发明尿囊素的添加量为0.6-1％，在分子上接入易溶于水的结构相似物，从而大大地改善了尿囊素的水溶性，可清除外层角质，疏通毛囊，促进微循环，改善和均匀肤色；促进细胞组织生长，加快伤口愈合；具有优异的抗过敏作用，增强肌肤免疫力；能够长效补水保湿，维持皮肤湿度，调节肌肤水油平衡。
B.复合生物酶
复合生物酶由多种酶组合而成，可实现多种酶的催化功效：抑菌消炎，清除自由基，抗衰老，修复肌肤和粘膜屏障。通过其接触上皮细胞，利用细胞自身的代谢物H2O，脱氢集氧，能够使细胞的含氧量迅速提升，并能够激活沉睡和亚休眠状态的细胞，促进细胞更新和组织代谢，促进细胞进行囊泡转运，当皮肤的微循环打通后，皮肤清除自由基和运输养料的通道更加通畅，根本解决肌肤的主动吸收问题，当皮肤的微循环打通后可促进上皮细胞得到修复增生，解决因细胞缺水缺氧造成的一系列皮肤问题，恢复肌肤弹性，紧致肌肤，愈合创伤，快速消肿。
多种酶复合可分解多余角质和毛孔污垢，深层清洁肌肤，对真菌有极强的灭活作用，蛋白酶可分解蛋白质，真菌的细胞壁主要成分为纤维蛋白，细胞壁破裂，胞浆释放，真菌凋亡。经临床试验，本发明复合生物酶能有效杀灭包括金黄色葡萄球菌、大肠杆菌、白色念珠菌在内的80多种有害菌，靶向调理和预防各种妇科疾病。
C.苦参提取物
苦参提取物可抑菌消炎，杀菌消肿，清热解毒，驱虫排浊，祛味止痒，其主要成分是生物碱类和黄酮类，生物碱类中的苦参碱对金黄色葡萄球菌、大肠杆菌、白色念珠菌等具有良好的抑制作用，具有抗滴虫、抗阿巴米虫的作用，可有效预防滴虫性阴道炎。黄酮类成分是酪氨酸酶的非竞争性抑制剂，辅助所述酪氨酸酶抑制剂的作用，减少黑色素的生成，美白嫩肤。
D.芦荟提取物
芦荟提取物含有蒽醌类化合物、多糖、有机酸、氨基酸、维生素、矿物质和活性酶等有效成分，可补水保湿，滋润紧致，避免干涩、瘙痒和肌肤松弛，深层清洁，抑菌消炎，修复黏膜，促进伤口愈合。
E.金缕梅提取物
金缕梅提取物可调节皮脂分泌，长效补水，持久保湿，美白滋养，紧致嫩肤，消炎抗敏，促进血液循环，改善微循环，修复黏膜屏障，维持恢复肌肤年轻态。
进一步的，所述增稠剂为卡波姆0.5-0.8％和三乙醇胺0.2-0.6％。
进一步的，所述复合生物酶包括纤维蛋白酶、溶菌酶、超氧化物歧化酶(SOD)、辅酶Q10、谷胱甘肽过氧化物酶。
进一步的，所述复合生物酶中纤维蛋白酶、溶菌酶、超氧化物歧化酶(SOD)、辅酶Q10、谷胱甘肽过氧化物酶的质量比为3-9：1-3：1-3：1-3：1-3。
进一步的，还包括防腐剂1-7％。
进一步的，所述防腐剂为辛酰羟肟酸0.2-3％和乙基己基甘油1-4％。
一种所述的生物酶消炎抑菌修护凝胶的制备方法，包括以下步骤：将增稠剂、尿囊素、丁二醇和水加入乳化锅中加热至85-90℃，恒温搅拌5-15min,降温至40-45℃，加入复合生物酶、苦参提取物、芦荟提取物和金缕梅提取物，搅拌10-30min，即得凝胶。
本发明具有如下有益效果：
本发明通过复合生物酶和植物提取物复配，复合生物酶的活性成分中含有丰富的微量元素，微量元素在接触肌肤，进入至肌肤内部后，能够有效的脱氢给氧，迅速为细胞供氧，加速细胞代谢，激发细胞活性，改善微循环，提高私处粘膜免疫，为上皮细胞提供能量，加速修复受损细胞，高效杀菌，持久抑菌，有效预防炎症反复发作。植物提取物可除菌抑菌，驱虫杀虫，排毒止痒，清爽祛味，激活自体免疫和细胞自愈能力，镇静消炎，快速消肿，收敛紧致肌肤。本发明修护凝胶可深层清洁，抑菌消炎，驱虫止痒，消肿祛除味，补水保湿，紧致抗衰，美白嫩肤，调节私处菌群平衡，维持弱酸环境，促进肌肤组织再生，加速创伤愈合，修复黏膜破损，提高肌肤黏膜自身免疫力，维持肌肤稳态，激发肌肤年轻态，靶向预防和缓解各种妇科疾病。见效快，针对轻中度的各种妇科疾病使用后当天见效，疗效好，使用2-3天症状减轻，使用6-10天基本痊愈。
具体实施方式
下面结合实施例对本发明进行详细的说明，实施例仅是本发明的优选实施方式，不是对本发明的限定。
下表是本发明生物酶消炎抑菌修护凝胶3个实施例和3个对比例的配方表(单位：％)：
所述的生物酶消炎抑菌修护凝胶的制备方法，包括以下步骤：将增稠剂、尿囊素、丁二醇和水加入乳化锅中加热至85℃，恒温搅拌10min,降温至45℃，加入复合生物酶、苦参提取物、芦荟提取物和金缕梅提取物，搅拌20min，即得凝胶。
一、抑菌效果
对本发明生物酶消炎抑菌修护凝胶3个实施例和3个对比例进行抑菌性能测试：
1.菌种：试验指标菌包括大肠杆菌(8099)、金黄色葡萄球菌(ATCC6538)和白色念珠菌(ATCC10231)；
2.菌悬液的制备：将菌种接种于培养基斜面，培养后用磷酸盐缓冲液洗去斜面上菌苔，混匀后计数，制备成符合含菌量要求的菌悬液；
3.抑菌试验：在无菌试管中加入样品(阳性对照组采用磷酸盐缓冲液)5mL与菌悬液0.1mL混匀，作用至设计规定的时间。取充分混匀的样液0.1mL接种无菌平皿，立即倒入融化并冷却至45℃的琼脂培养基中混匀。待凝固后，将各接种平板置于37℃条件下培养49小时后观察结果，计算抑菌率；
4.计算公式：抑菌率(％)＝(阳性对照组平均菌数-实验组平均菌数)/阳性对照组平均菌数×100％；
5.测试结果见下表：
可见，本发明可快速、有效杀灭大肠杆菌、金黄色葡萄球菌和白色念珠菌。
二、抗炎效果
对本发明生物酶消炎抑菌修护凝胶3个实施例和3个对比例进行抗炎效果测试：
1.试验动物：选取6只体重差不超过±2g的成体雌性小鼠，分为6组；
2.试验环境：温度22℃，湿度60％，单笼喂养；
3.试验方法：分别每天在小鼠的左耳涂抹1mL样品(对照组涂抹生理盐水)，涂抹7天后，在小鼠的左耳涂抹0.03mL二甲苯致炎，继续在小鼠的左耳涂抹1mL女性洁净抑菌滋润护理液1天；然后脱颈处死小鼠，用直径8mm的冲子沿耳廓边缘一次性冲下小鼠的左耳片和右耳片，保持二耳冲的部位保持一致，称重，以左耳和右耳片的重量差作为肿胀度；
4.肿胀抑制率的计算公式为：肿胀抑制率(％)＝(对照组肿胀度-试验组肿胀度)/对照组肿胀度×100％；
5.测试结果见下表：
| 样品 | 实施例1 | 实施例2 | 实施例3 | 对比例1 | 对比例2 | 对比例3 |
| 肿胀抑制率/％ | 83.2 | 84.8 | 86.5 | 70.1 | 76.9 | 81.3 |
可见，本发明可镇静消肿。
三、妇科疾病治疗效果
1.试验人员：选取120名身体其他各项指标合格、年龄25-35岁的患者，其中，60人为有阴道瘙痒症状的阴道炎患者；60人为一度宫颈糜烂患者；分为6组，每组阴道炎患者和宫颈糜烂患者各10人；
2.试验方法：使用1％的新洁尔灭对患者的外阴、阴道及宫颈进行消毒拭阴道分泌物后，施用样品于患者的外阴、阴道及宫颈，治疗周期为7天，于每天早晚各施用一次；
3.治疗效果判断标准：患者经过治疗后创面完全愈合，宫颈局部黏膜光滑，无宫颈溃疡情况，或无瘙痒、无炎症情况，视为显效；患者创面基本愈合，宫颈局部黏膜较为光滑，宫颈溃疡情况或炎症情况改善，视为有效；患者经过治疗后，患者创面未愈合，炎症未消退以及临床症状未得到任何改善视为无效；
4.实验结果见下表：
试验周期结束30天后，实施例1-3显效患者瘙痒、阴道炎和宫颈糜烂症状均无复发。可见，本发明可有效缓解和治愈瘙痒、阴道炎和宫颈糜烂等妇科疾病，见效快，疗效好，可有效避免症状反复发作。
本发明凝胶可有效清除自由基，抗氧化，延缓衰老，滋养嫩白，杀菌消炎，抑菌消肿，清洁排毒，驱虫止痒，修复黏膜，愈合损伤，护理子宫，保养卵巢，调经止痛，保湿滋润，收缩紧致阴道，防止干涩，靶向调理和预防各种妇科疾病，改善私处环境，修复黏膜屏障功能，赋活细胞，激发子宫环境年轻态。
Claims (7)
1.一种生物酶消炎抑菌修护凝胶，其特征在于，包括以下按质量百分比计算的组分：增稠剂0.7-1.4％、尿囊素0.6-1％、复合生物酶0.5-1％、丁二醇1-3％、苦参提取物0.1-0.5％、芦荟提取物0.5-3％、金缕梅提取物8-15％以及余量的水。
2.根据权利要求1所述的生物酶消炎抑菌修护凝胶，其特征在于，所述增稠剂为卡波姆0.5-0.8％和三乙醇胺0.2-0.6％。
3.根据权利要求1所述的生物酶消炎抑菌修护凝胶，其特征在于，所述复合生物酶包括纤维蛋白酶、溶菌酶、超氧化物歧化酶、辅酶Q10、谷胱甘肽过氧化物酶。
4.根据权利要求3所述的生物酶消炎抑菌修护凝胶，其特征在于，所述复合生物酶中纤维蛋白酶、溶菌酶、SOD、辅酶Q10、谷胱甘肽过氧化物酶的质量比为3-9：1-3：1-3：1-3：1-3。
5.根据权利要求1所述的生物酶消炎抑菌修护凝胶，其特征在于，还包括防腐剂1-7％。
6.根据权利要求5所述的生物酶消炎抑菌修护凝胶，其特征在于，所述防腐剂为辛酰羟肟酸0.2-3％和乙基己基甘油1-4％。
7.一种权利要求1-6任一项所述的生物酶消炎抑菌修护凝胶的制备方法，其特征在于，包括以下步骤：将增稠剂、尿囊素、丁二醇和水加入乳化锅中加热至85-90℃，恒温搅拌5-15min,降温至40-45℃，加入复合生物酶、苦参提取物、芦荟提取物和金缕梅提取物，搅拌10-30min，即得凝胶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110922711.4A CN113633761A (zh) | 2021-08-12 | 2021-08-12 | 一种生物酶消炎抑菌修护凝胶及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110922711.4A CN113633761A (zh) | 2021-08-12 | 2021-08-12 | 一种生物酶消炎抑菌修护凝胶及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113633761A true CN113633761A (zh) | 2021-11-12 |
Family
ID=78420973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110922711.4A Pending CN113633761A (zh) | 2021-08-12 | 2021-08-12 | 一种生物酶消炎抑菌修护凝胶及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113633761A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306400A (zh) * | 2022-01-25 | 2022-04-12 | 碱蓬先创科技(盘锦)有限公司 | 一种碱蓬私密护理中药凝胶 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590222A (zh) * | 2008-05-26 | 2009-12-02 | 刘安荣 | 一种sod细胞修复液及其制备方法 |
| CN108938517A (zh) * | 2018-08-16 | 2018-12-07 | 肖渭强 | 一种女性私处护理组合物、其制备方法及护理膜 |
| CN109395069A (zh) * | 2018-08-12 | 2019-03-01 | 丽申生物科技(上海)有限公司 | 一种含复合酶的女性生殖道修复凝胶及其制备方法 |
| CN110123695A (zh) * | 2019-06-03 | 2019-08-16 | 惠州学院 | 一种细胞能量修复组合物 |
-
2021
- 2021-08-12 CN CN202110922711.4A patent/CN113633761A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590222A (zh) * | 2008-05-26 | 2009-12-02 | 刘安荣 | 一种sod细胞修复液及其制备方法 |
| CN109395069A (zh) * | 2018-08-12 | 2019-03-01 | 丽申生物科技(上海)有限公司 | 一种含复合酶的女性生殖道修复凝胶及其制备方法 |
| CN108938517A (zh) * | 2018-08-16 | 2018-12-07 | 肖渭强 | 一种女性私处护理组合物、其制备方法及护理膜 |
| CN110123695A (zh) * | 2019-06-03 | 2019-08-16 | 惠州学院 | 一种细胞能量修复组合物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306400A (zh) * | 2022-01-25 | 2022-04-12 | 碱蓬先创科技(盘锦)有限公司 | 一种碱蓬私密护理中药凝胶 |
| CN114306400B (zh) * | 2022-01-25 | 2023-11-21 | 广东赛尔生物科技有限公司 | 一种碱蓬私密护理中药凝胶 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Subrahmanyam | Topical application of honey in treatment of burns | |
| CN105012993A (zh) | 一种阳离子医用生物胶抗菌敷料及其制备方法 | |
| CN108420789B (zh) | 一种苯扎氯铵外用溶液及其制备方法 | |
| CN113081928B (zh) | 一种植物抑菌凝胶及其制备方法和应用 | |
| CN102988231A (zh) | 一种女性护理液及其制备方法 | |
| CN109528982A (zh) | 一种用于妇科炎症的臭氧油凝胶及其制备方法 | |
| CN108158995A (zh) | 一种含有壳聚糖的妇科用抗菌泡沫剂及其制备方法 | |
| CN105168238A (zh) | 一种透明质酸温敏凝胶及其制备方法和应用 | |
| CN109771368A (zh) | 一种抑菌凝胶及其制备方法 | |
| CN101780031A (zh) | 一种用于修复皮肤创面或宫颈粘膜的诱导凝胶 | |
| CN111449973A (zh) | 一种修复女性阴道微生态平衡的泡沫剂及其制备方法 | |
| CN113633761A (zh) | 一种生物酶消炎抑菌修护凝胶及其制备方法 | |
| CN109010124B (zh) | 一种海洋精粹妇科抑菌凝胶及其制备方法 | |
| CN115770195B (zh) | 一种稳定的祛痘组合物及其制备方法 | |
| EA005917B1 (ru) | Вирулицидные композиции | |
| CN109432204B (zh) | 一种银离子喷雾及其制备方法 | |
| CN113456735B (zh) | 一种灭活益生菌草本凝胶及其制备方法和应用 | |
| Cornbleet | Self-Sterilizing Powers of the Skin: V. Are They Endowed by the Surface Acid? | |
| CN116236439A (zh) | 一种胶态银抑菌凝胶及其制备方法和应用 | |
| CN105999224B (zh) | 一种仿生型妇科洗液及其制备方法 | |
| CN111920911B (zh) | 一种防蚊消毒剂及制备方法 | |
| CN110623919A (zh) | 一种妇科用富含氢离子酸性养护避孕凝胶及其制备方法 | |
| Mahmood et al. | Evaluation of in vivo wound healing activity of Chromolaena odorata leaf extract on excision wounds model in rats | |
| CN112870311A (zh) | 一种女性私密处抑菌水凝胶及使用方法 | |
| CN106176916A (zh) | 一种女性阴道平衡护理液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |